Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.43 |
| ▸ | PYGL | P06737 | 3/20 | 0.43 |
| ▸ | PYGM | P11217 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10601972 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL7590934 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL8946124 | 0.77 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL18927292 | 0.77 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL3712334 | 0.77 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL3481602 | 0.77 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL6302580 | 0.77 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL18927294 | 0.77 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL14597956 | 0.77 | PYGB (0.42) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL30998836 | 0.74 | MEN1 (0.64) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544453-B2 | Amphotericin B conjugated stabilized gold nanoparticles and uses thereof | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2026-02-10 | — | — | US | claimed |
| US-20230061519-A1 | AMPHOTERICIN B CONJUGATED STABILIZED GOLD NANOPARTICLES AND USES THEREOF | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-03-02 | — | — | US | claimed |
| US-12544453-B2 | Amphotericin B conjugated stabilized gold nanoparticles and uses thereof | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2026-02-10 | — | — | US | disclosed |
| US-20230061519-A1 | AMPHOTERICIN B CONJUGATED STABILIZED GOLD NANOPARTICLES AND USES THEREOF | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20230061519-A1 | AMPHOTERICIN B CONJUGATED STABILIZED GOLD NANOPARTICLES AND USES THEREOF | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230061519-A1 | AMPHOTERICIN B CONJUGATED STABILIZED GOLD NANOPARTICLES AND USES THEREOF | ALG1, CD47, FUT6 | PYGB 2385/4885PYGL 2697/4885PYGM 3039/4885 |
| US-12544453-B2 | Amphotericin B conjugated stabilized gold nanoparticles and uses thereof | FUT6, ST6GAL1, ALG1 | PYGB 1925/4885PYGL 2450/4885PYGM 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.